In vitro study reveals that nortrachelogenin suppresses NF-κB signaling and osteoclast formation in precursors, suggesting therapeutic potential for bone loss.
Nortrachelogenin is a dibenzylbutyrolactone lignan associated with redox-sensitive signaling. We examined its effects on receptor activator of nuclear factor kappa-B ligand (RANKL)-induced nuclear factor kappa-B (NF-κB) activation in osteoclast precursors. Nortrachelogenin attenuated IκB phosphorylation and degradation and reduced p65 phosphorylation. Consistently, it markedly decreased the formation of tartrate-resistant acid phosphatase (TRAP)-positive multinucleated osteoclasts. These findings identify nortrachelogenin as a lignan scaffold that suppresses nuclear factor kappa-B signaling and osteoclastogenesis in vitro.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: